N@N

Depomed, Inc. to Announce Fourth Quarter and Year-End 2008 Financial Results on March 5, 2009

_{//health-fitness.news-articles.net/content/2009/ .. -end-2008-financial-results-on-march-5-2009.html}
^{Published in Health and Fitness on Thursday, February 19th 2009 at 9:18 GMT, Last Modified on 2009-02-19 09:19:06 by Market Wire}  

MENLO PARK, Calif.--([ BUSINESS WIRE ])--Depomed, Inc. (NASDAQ:DEPO) announced today that it will release fourth quarter and year-end results for 2008 after the market closes on Thursday, March 5, 2009. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results.

The conference call will be available via a live webcast on the investor relations section of Depomed's website at [ http://www.depomedinc.com ]. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm^TM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA^® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin^® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate DM-5689 is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, [ www.depomedinc.com ].